Fundz

Amarna Therapeutics

Leiden, Netherlands · Biopharma, Biotechnology, Health Care

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVe

Key facts

Headquarters
Leiden, Netherlands
Employees
Unknown
Industries
Biopharma, Biotechnology, Health Care
Status
Private
Website
http://www.amarnatherapeutics.com/
LinkedIn
Company page

Recent activity at Amarna Therapeutics

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

Amarna Therapeutics funding history

DateRoundAmount
Dec 2021Funding Round$5.4M

Leadership

  • Aurelia Caparrós, Chief Business Officer
  • Henk Streefkerk, Chief Executive Officer

Verified email and direct lines for Amarna Therapeutics’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Companies similar to Amarna Therapeutics

About Amarna Therapeutics: questions and answers

What does Amarna Therapeutics do?

Amarna Therapeutics is a privately held, pre-clinical biotech company developing transformative, potentially curative gene therapies for a range of rare and prevalent diseases. The company is pioneering the development of gene therapies based on simian virus 40 (SV40), a macaque polyoma virus to which humans are immunologically naïve. Amarna has created a proprietary production cell line (SuperVe

Where is Amarna Therapeutics headquartered?

Amarna Therapeutics is headquartered in Leiden, Netherlands.

Has Amarna Therapeutics raised funding?

Yes. Fundz has recorded 1 funding event for Amarna Therapeutics. The most recent, Funding Round of $5.4M, was in Dec 2021.

Who leads Amarna Therapeutics?

Henk Streefkerk is a Chief Executive Officer at Amarna Therapeutics.

What is the latest news on Amarna Therapeutics?

On Jul 9, 2025, Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy for Type 1 Diabetes.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Amarna Therapeutics across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.